Clearside Biomedical Files 8-K

Ticker: CLSDQ · Form: 8-K · Filed: Jul 24, 2024 · CIK: 1539029

Clearside Biomedical, Inc. 8-K Filing Summary
FieldDetail
CompanyClearside Biomedical, Inc. (CLSDQ)
Form Type8-K
Filed DateJul 24, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Clearside Biomedical filed an 8-K on 7/24/24, likely containing important company updates.

AI Summary

On July 24, 2024, Clearside Biomedical, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Clearside Biomedical is providing updates or disclosures to the SEC, which could contain important information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing header and does not contain specific material events or financial data that would indicate a change in risk.

Key Players & Entities

  • Clearside Biomedical, Inc. (company) — Registrant
  • July 24, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 678 270-3631 (phone_number) — Registrant's Telephone Number

FAQ

What is the primary purpose of this 8-K filing for Clearside Biomedical, Inc.?

The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits, as of July 24, 2024.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is July 24, 2024.

In which state is Clearside Biomedical, Inc. incorporated?

Clearside Biomedical, Inc. is incorporated in Delaware.

What is the principal executive office address for Clearside Biomedical, Inc.?

The address is 900 North Point Parkway, Suite 200, Alpharetta, Georgia, 30005.

What is the telephone number listed for Clearside Biomedical, Inc.?

The telephone number is 678-270-3631.

Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-07-24 07:55:18

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On July 24, 2024, Clearside Biomedical, Inc. (the " Company ") will host a virtual Suprachoroidal Delivery KOL Webinar (the " Webinar "). [A webcast of the Webinar will be available through the Events and Presentations page of the Investors section of the Company's website.] The Webinar will include a slide presentation. A copy of this slide presentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Company Presentation. 104 The cover page from Clearside Biomedical, Inc.'s Form 8-K filed on July 24, 2024, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 24, 2024 CLEARSIDE BIOMEDICAL, INC. By: /s/ Charles A. Deignan Name: Charles A. Deignan Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.